Lv5
850 积分 2021-11-08 加入
A Nomogram for Predicting Progression-Free Survival in Primary Extramedullary Multiple Myeloma Using Routine Laboratory Variables
10天前
已完结
Carfilzomib–lenalidomide–dexamethasone versus lenalidomide–dexamethasone in patients with newly diagnosed myeloma ineligible for autologous stem-cell transplantation (EMN20): a randomised, open-label, multicentre, phase 3 trial
11天前
已完结
Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial
11天前
已完结
Phase 1 pilot study for hemophilia-A: AAV8 vector with prophylactic tacrolimus-glucocorticoid achieves therapeutic FVIII activity
1个月前
已完结
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
1个月前
已完结
Measurable residual disease assessment in multiple myeloma
1个月前
已完结
Efficacy and Safety Comparisons of Four Approved Chimeric Antigen Receptor T‐Cell Therapies in Multiple Myeloma
1个月前
已完结
Past, Present, and Future of Dexamethasone in Multiple Myeloma and AL Amyloidosis
1个月前
已完结
CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus
1个月前
已完结
Optimizing Allogeneic Chimeric Antigen Receptor T-Cell Persistence in Relapsed/Refractory Large B-Cell Lymphoma: The Role of KIR Matching
1个月前
已完结
皖公网安备34019202002308
